Statistics have recently shown that traumatic brain injuries will be the world’s third leading cause of death and disability by 2020, which is why efforts to find new treatments en route to an eventual cure have been ramped up in recent years. Fortunately, with advancements in modern science and technology, scientists and medical researchers have been able to learn more about TBI in recent years than ever before, and new treatments and breakthroughs are occurring at seemingly spectacular rates.
Such a breakthrough was recently achieved by a team of researchers the University of Pennsylvania’s School of Engineering and Applied Science, as members of the Department of Bioengineering have identified a drug that may be able to encourage injury reversal...Read More »
Tomorrow, researchers from the Kennedy Krieger Institute and the Brain Injury Association of Maryland will host a forum on traumatic brain injuries at the U.S. Army’s Aberdeen Proving Ground facilities in Aberdeen, Maryland. The forum will begin at 1 PM ET and last until 4 PM ET in the APG’s post theater, and the audience in attendance will have the opportunity to participate in an interactive exercise that will deal in sensory and perception simulation, as well as a question and answer session with the researchers and experts on hand.
However, there is good news for a significant number of people who are unable to attend tomorrow’s event – it will be broadcast to at least 15 military installations across the U.S., according to the U.S. Army...Read More »
The drug Suramin was first developed in 1916 by two German scientists as a means of treating African sleeping sickness, which is a potentially fatal disease that is characterized by humans generally feeling tired and sleeping during the daytime, while remaining awake at night. The drug is still produced and sold by pharmaceutical giant Bayer under the name Germanin; however, it hadn’t been used or tested for any additional illnesses or diseases until very recently.
In a study conducted by researchers from the University of California-San Diego’s School of Medicine, it was determined that Suramin, which is also known as an antipurinergic therapy mediator, was successful in reversing and restoring autism symptoms in the brains of mice....Read More »